PDS Biotechnology (FRA:EU6) Short Interest


FRA:EU6 PDS Biotechnology Corp FRA:EU6
31 GF Score
Price €0.77
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:EU6 vs INKT, PMVP, EDSA: Short Interest Comparison

For the Biotechnology subindustry, PDS Biotechnology's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PDS Biotechnology Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Short Interest distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Short Interest falls into.


FRA:EU6
31GF Score
PDS Biotechnology Corp FRA:EU6
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
31GF Score

Get the complete analysis for FRA:EU6

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price